Novavax Vaccine 96.4% Effective against Original Coronavirus
Gaithersburg: Biotechnology company Novavax has announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom (U.K.) of NVX–CoV2373, the…